DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

New kits are designed to offer a convenient method to label any antibody with one of Bio-Rad’s StarBright Dyes.

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting ...

As global markets grapple with tariff uncertainties and mixed economic signals, major indices such as the S&P 500 and Nasdaq Composite have shown modest declines, reflecting investor caution amid ...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including ...

Bolt Biotherapeutics (BOLT) announced that the target of their worldwide co-development collaboration with Toray Industries is Caprin-1, a ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Plants droop and shed their leaves when parched, but with a splash of water, their stems regain strength and their leaves ...